Stratification of biologic use and outcomes within
Age-of-onset/sex clusters
Within our biologic (OMA+ MEPO) cohort, the female/early-onset cluster
was most prevalent, while the male/early-onset group was the least.
Although biologic use across these phenotypes (Table 4) was
significantly different, there was no statistically significant
difference in response for either biologic across these phenotypes.